Lata Adnani

Lata Adnani

Auto-generated profile, based on publicly available information

Lata Adnani

Sunnybrook Research Institute, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
NTNadim Tawil
Nadim Tawil
RBRayhaan Bassawon
Rayhaan Bassawon
BMBrian Meehan
Brian Meehan
ANAli Nehme
Ali Nehme
LMLaura Montermini
Laura Montermini
JRJanusz Rak
Janusz Rak
Vascular anomalies, including local and peripheral thrombosis, are a hallmark of glioblastoma (GBM) and an aftermath of deregulation of the cancer cell genome and epigenome. Although the molecular effectors of these changes are poorly understood, the upregulation of podoplanin (PDPN) by cancer cells has recently been linked to an increased risk for venous thromboembolism (VTE) in GBM patients. Therefore, regulation of this platelet-activating protein by transforming events in cancer cells is of considerable interest. We used single-cell and bulk transcriptome data mining, as well as cellular and xenograft models in mice, to analyze the nature of cells expressing PDPN, as well as their impact on the activation of the coagulation system and platelets. We report that PDPN is expressed by distinct (mesenchymal) GBM cell subpopulations and downregulated by oncogenic mutations of EGFR and IDH1 genes, along with changes in chromatin modifications (enhancer of zeste homolog 2) and DNA methylation. Glioma cells exteriorize their PDPN and/or tissue factor (TF) as cargo of exosome-like extracellular vesicles (EVs) shed from cells in vitro and in vivo. Injection of glioma-derived podoplanin carrying extracelluar vesicles (PDPN-EVs) activates platelets, whereas tissue factor carrying extracellular vesicles (TF-EVs) activate the clotting cascade. Similarly, an increase in platelet activation (platelet factor 4) or coagulation (D-dimer) markers occurs in mice harboring the corresponding glioma xenografts expressing PDPN or TF, respectively. Coexpression of PDPN and TF by GBM cells cooperatively affects tumor microthrombosis. Thus, in GBM, distinct cellular subsets drive multiple facets of cancer-associated thrombosis and may represent targets for phenotype- and cell type–based diagnosis and antithrombotic intervention.

3 April 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
CSCristiana Spinelli
Cristiana Spinelli
LALata Adnani
Lata Adnani
BMBrian Meehan
Brian Meehan
LMLaura Montermini
Laura Montermini
SHSidong Huang
Sidong Huang
JRJanusz Rak
Janusz Rak
Targeting neovascularization in glioblastoma (GBM) is hampered by poor understanding of the underlying mechanisms and unclear linkages to tumour molecular landscapes. Here we report that different molecular subtypes of human glioma stem cells (GSC) trigger distinct endothelial responses involving either angiogenic or circumferential vascular growth (vasectasia). The latter process is selectively triggered by mesenchymal (but not proneural) GSCs and is mediated by a subset of extracellular vesicles (EVs) able to transfer EGFR/EGFRvIII transcript to endothelial cells. Inhibition of the expression and phosphorylation of EGFR in endothelial cells, either pharmacologically (Dacomitinib) or genetically (gene editing), abolishes their EV responses in vitro and disrupts vasectasia in vivo. Therapeutic inhibition of EGFR markedly extends anticancer effects of VEGF blockade in mice, coupled with abrogation of vasectasia and prolonged survival. Thus, vasectasia driven by intercellular transfer of oncogenic EGFR may represent a new therapeutic target in a subset of GBMs.

19 September 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
LALata Adnani
Lata Adnani
JKJordan Kassouf
Jordan Kassouf
BMBrian Meehan
Brian Meehan
CSCristiana Spinelli
Cristiana Spinelli
NTNadim Tawil
Nadim Tawil
JRJanusz Rak
Janusz Rak
Glioblastoma (GBM) is an incurable form of primary astrocytic brain tumor driven by glioma stem cell (GSC) compartment closely associated with the vascular niche. GSC phenotypes are heterogeneous and range from proneural to mesenchymal-like, the latter characterised by greater invasiveness. Here we document the secretory (angiocrine) role of endothelial cells and their derived extracellular vesicles (EVs) as drivers of proneural-to-mesenchymal reprogramming of GSCs. These changes involve activation of matrix metalloproteinases (MMPs) and NFκB, and inactivation of NOTCH, while altering responsiveness to chemotherapy and driving infiltrative growth in the brain. Our findings suggest that EV-mediated angiocrine interactions impact the nature of cellular stemness in GBM with implications for disease biology and therapy.

23 May 2025 in Science Advances
Verified
Journal Article
Open access
LALata Adnani
Lata Adnani
BMBrian Meehan
Brian Meehan
MKMinjun Kim
Minjun Kim
DCDongsic Choi
Dongsic Choi
CRChristopher E. Rudd
Christopher E. Rudd
JRJanusz Rak
Janusz Rak
Aggressive brain tumors often exhibit immunologically ‘cold’ microenvironment, where the vascular barrier impedes effective immunotherapy in poorly understood ways. Tumor vasculature also plays a pivotal role in immunoregulation and antitumor immunity. Here, we show that small GTPase Rab27 controls the vascular morphogenesis and permeability for blood content and immune effectors. Thus, in Rab27a/b double knock out (Rab27-dKO) mice, the brain vasculature is abnormally scarce, while the blood vessels become dysmorphic and hyperpermeable in the context of brain tumors, including syngeneic glioblastoma. These defects are reflected in rearrangements of endothelial cell subpopulations with underlying diminution of venous endothelial subtype along with changes in gene and protein expression. Notably, Rab27-dKO brain endothelial cells exhibit deficient tight junctions, whereby they enable large-scale extravasation of cytotoxic T cells into the tumor mass. We show that Rab27-regulated vascular T cell infiltration can be exploited to enhance adoptive T cell therapy in syngeneic brain tumors.

18 March 2026 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
YTYacine Touahri
Yacine Touahri
APAlissa Pak
Alissa Pak
LDLuke Ajay David
Luke Ajay David
JHJoseph Hanna
Joseph Hanna
HLHedy Liu
Hedy Liu
CSCarol Schuurmans
Carol Schuurmans
Müller glia arise from late-stage retinal progenitor cells (RPCs) as a distinct lineage that diverges from neurogenic trajectories. Here, we identify the maternally imprinted gene Plagl1 as a key transcriptional regulator of gliogenesis in the murine retina. Plagl1 is expressed during the RPC-to-glia transition and is dynamically regulated in Müller glia following injury. To define its developmental role, we analyzed Plagl1 ⁺/⁻pat null mutant retinas at postnatal day 7 (P7), when central retinal gliogenesis is complete. In the absence of Plagl1 , Sox9 ⁺ glial/precursor cells were displaced and proliferated ectopically, with structural dysmorphologies, reactive gliosis, and impaired visual processing persisting into later postnatal stages. Bulk RNA-seq and ATAC-seq revealed widespread reductions in chromatin accessibility and transcriptional dysregulation affecting epigenetic modifiers, translational machinery, fate-specifying transcription factors, cell cycle regulators, and signaling pathways. Single-cell pseudobulk analysis showed that Plagl1 loss disrupts chromatin, transcriptional, and translational programs specifically within Sox9 ⁺ cells, encompassing Müller glia and precursor populations, pinpointing these cells as the source of defects in Plagl1 ⁺/⁻pat retinas. Notch signaling was elevated in Plagl1 -deficient glia, and genetic activation at P14 displaced Sox9 ⁺ glial cells, without inducing proliferation. Similarly, conditional deletion of Plagl1 in postnatal Müller glia at P14 disrupted positioning and not cell cycle exit, confirming a cell-autonomous requirement for Müller glia positioning that is independent of proliferation control. Since these conditional manipulations could only be performed at P14 at the earliest, they reveal Plagl1 ’s later functions in postmitotic glia and complement, rather than mirror, the earlier P7 mixed RPC/glial null phenotype. Together these findings establish Plagl1 as a critical regulator of the late-stage RPC to Müller glia transition, acting through coordinated control of chromatin accessibility and gene expression programs to ensure timely cell cycle exit. This function aligns with Plagl1 ’s broader tumor suppressor role in stabilizing postmitotic, differentiated cell states across tissues.

16 May 2024 in Bleeding, Thrombosis and Vascular Biology
Verified
Journal Article
Open access
PDF file
NTNadim Tawil
Nadim Tawil
LALata Adnani
Lata Adnani
JRJanusz Rak
Janusz Rak
Cancer-associated thrombosis (CAT) results from the hemostatic system being dysregulated by the progression of cancer. Despite common clinical manifestations, the mechanisms of CAT may vary greatly because cancers develop along distinct biological trajectories that are imposed by the interaction between the tumor cell genome, the epigenome, the surrounding microenvironment, and the tissue of origin. The coagulome, or repertoire of coagulation effectors, expressed by stromal, inflammatory, and cancer cells at the tumor-vascular interface and systemically, reflects this biological variability. Complex landscapes of coagulant and non-coagulant cellular populations are revealed by single-cell RNA sequencing analyses conducted on unperturbed human cancer tissues. Additionally, through mediators of cell-cell interactions, soluble coagulants, and extracellular vesicles containing tissue factor, podoplanin, and other effectors, coagulomes are projected into the pericellular milieu and systemic circulation. As this complexity is currently outside of the clinical paradigm, one could argue that better CAT management could result from a more individualized analysis of coagulomes in cancer patients.